Immatics N.V
NASDAQ:IMTX
| Market Cap (Intraday) | 596.42M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.50 |
| 50-Day MA | $5.94 |
| 200-Day MA | $5.73 |
Immatics N.V Stock, NASDAQ:IMTX
Paul-Ehrlich-Strasse 19, Tuebingen, Baden Wuerttemberg 72076
Germany
Phone: +49.7071.5397.0
Number of Employees: 343
Description
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.